+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals)

  • ID: 4412653
  • Report
  • October 2017
  • Region: United Kingdom, Europe, Germany, France, Italy, Spain
  • 86 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Insulet Corporation
  • Medtronic
  • Tandem Diabetes Care
  • MORE

According to the Europe Multiple Sclerosis Market report, potential is more than US$ 5 Billion by 2022. But only more than half this market is expected to be actually achieved. This huge difference between actual market and unmet market is due to gap between number of patients who require multiple sclerosis drugs and number of patients who are receiving disease modifying therapy.  

Orals mode of administration is Fast growing disease modifying therapy in the European region

Orals mode of administration is fast growing disease modifying therapy in the European region. Injectables and infusions multiple sclerosis therapies are steadily losing their ground in the European market.

Germany is the clear winner in the Europe multiple sclerosis market

In the Europe multiple sclerosis market, Germany is the clear winner, but its losing its market share year on year. The other important markets in the European region are France, Italy, Spain and United Kingdom.

Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals) on Multiple Sclerosis Market. This 86 page report with 73 figures and 1 Tables provides 5 Countries: actual and unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration.
 
Actual Market is the current market which is already present

Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

Top 5 Countries Multiple Sclerosis Market & Patients Treated

  1. United Kingdom
  2. Germany
  3. France
  4. Italy
  5. Spain

Mode of administration - Market & Patients Treated

  1. Injectables
  2. Infusions
  3. Orals

Key Questions Answered in the Report?  

  • What is the Europe multiple sclerosis market and its growth potential in near future?
  • How many number of patients treated by disease modifying therapy in the European region?
  • What is the multiple sclerosis market in European countries (UK, Germany, France, Italy, and Spain)?
  • How many multiple sclerosis patients living in European countries?
  • Which mode of administration (Injectables, Infusions, Orals) is gaining more popularity?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Insulet Corporation
  • Medtronic
  • Tandem Diabetes Care
  • MORE

1 Executive Summary

2 Europe Multiple Sclerosis Patient Numbers (2011-2022)
2.1 Patient Number & Forecast
2.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3 By Mode of Administration - Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3.1 Injectables Patients Numbers
2.3.2 Infusions Patients Numbers
2.3.3 Orals Patient Numbers

3 Europe Multiple Sclerosis Market (2011-2022)
3.1 Unmet Market & Forecast
3.2 Market & Forecast
3.3 By Mode of Administration - Market & Forecast
3.3.1 Injectables Market
3.3.2 Infusions Market
3.3.3 Orals Market

4 Europe Multiple Sclerosis Population Share (2011-2022)
4.1 Patient Numbers Share & Forecast
4.2 Disease-Modifying Therapy (DMT) Patient Numbers Share & Forecast
4.3 By Mode of Administration - Patient Numbers Share & Forecast

5 Europe Multiple Sclerosis Market Share (2011-2022)
5.1 By Countries-Unmet Market Share & Forecast
5.2 By Countries-Market Share & Forecast
5.3 By Mode of Administration Market Share & Forecast

6 United Kingdom
6.1 Multiple Sclerosis Patient Numbers (2011-2022)
6.1.1 Patient Number & Forecast
6.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
6.2 Multiple Sclerosis Market (2011-2022)
6.2.1 Unmet Market & Forecast
6.2.2 Market & Forecast

7 France
7.1 Multiple Sclerosis Patient Number (2011-2022)
7.1.1 Patient Number & Forecast
7.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
7.2 Multiple Sclerosis Market (2011-2022)
7.2.1 Unmet Market & Forecast
7.2.2 Market & Forecast

8 Germany
8.1 Multiple Sclerosis Patient Number (2011-2022)
8.1.1 Patient Number & Forecast
8.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
8.2 Multiple Sclerosis Market (2011-2022)
8.2.1 Unmet Market & Forecast
8.2.2 Market & Forecast

9 Italy
9.1 Multiple Sclerosis Patient Number (2011-2022)
9.1.1 Patient Number & Forecast
9.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
9.2 Multiple Sclerosis Market (2011-2022)
9.2.1 Unmet Market & Forecast
9.2.2 Market & Forecast

10 Spain
10.1 Multiple Sclerosis Patient Number (2011-2022)
10.1.1 Patient Number & Forecast
10.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
10.2 Multiple Sclerosis Market (2011-2022)
10.2.1 Unmet Market & Forecast
10.2.2 Market & Forecast

11 Growth Drivers
11.1 Point no. 1

12 Challenges
12.1 Point no. 2
12.2 Multiple Sclerosis Drugs are Expensive
12.3 Difficult to Research on Multiple Sclerosis

13 Appendix

List of Figures:

Figure 2-1: Europe - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 2-2: Europe-Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 2-3: Europe - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 2-4: Europe-Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 2-5: Europe-Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011-2016
Figure 2-6: Europe-Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017-2022
Figure 2-7: Europe - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011-2016
Figure 2-8: Europe-Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017-2022
Figure 2-9: Europe - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011-2016
Figure 2-10: Europe-Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017-2022
Figure 3-1: Europe-Multiple Sclerosis Unmet Market (Million US$), 2011-2016
Figure 3-2: Europe-Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017-2022
Figure 3-3: Europe-Multiple Sclerosis Market (Million US$), 2011-2016
Figure 3-4: Europe-Forecast for Multiple Sclerosis Market (Million US$), 2017-2022
Figure 3-5: Europe-Multiple Sclerosis Injectables Market (Million US$), 2011-2016
Figure 3-6: Europe-Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017-2022
Figure 3-7: Europe-Multiple Sclerosis Infusions Market (Million US$), 2011-2016
Figure 3-8: Europe-Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017-2022
Figure 3-9: Europe-Multiple Sclerosis Orals Market (Million US$), 2011-2016
Figure 3-10: Europe-Forecast for Multiple Sclerosis Orals Market (Million US$), 2017-2022
Figure 4-1: Europe - Patient Numbers Share (Percent), 2011-2016
Figure 4-2: Europe-Forecast for Patient Numbers Share (Percent), 2017-2022
Figure 4-3: Europe - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011-2016
Figure 4-4: Europe-Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017-2022
Figure 4-5: Europe-Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011-2016
Figure 4-6: Europe-Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017-2022
Figure 4-7: Europe-Multiple Sclerosis Unmet Market Share (Percent), 2011-2016
Figure 4-8: Europe-Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017-2022
Figure 4-9: Europe-Multiple Sclerosis Market Share (Percent), 2011-2016
Figure 4-10: Europe-Forecast for Multiple Sclerosis Market Share (Percent), 2017-2022
Figure 4-11: Europe-Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011-2016
Figure 4-12: Europe-Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017-2022
Figure 5-1: United Kingdom-Multiple Sclerosis Patient Numbers (Thousand), 2011-2016
Figure 5-2: United Kingdom-Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017-2022
Figure 5-3: United Kingdom-Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011-2016
Figure 5-4: United Kingdom-Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017-2022
Figure 5-5: United Kingdom-Multiple Sclerosis Unmet Market (Million US$), 2011-2016
Figure 5-6: United Kingdom-Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017-2022
Figure 5-7: United Kingdom-Multiple Sclerosis Market (Million US$), 2011-2016
Figure 5-8: United Kingdom-Forecast for Multiple Sclerosis Market (Million US$), 2017-2022
Figure 6-1: France-Multiple Sclerosis Patient Numbers (Thousand), 2011-2016
Figure 6-2: France-Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017-2022
Figure 6-3: France-Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011-2016
Figure 6-4: France-Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017-2022
Figure 6-5: France-Multiple Sclerosis Unmet Market (Million US$), 2011-2016
Figure 6-6: France-Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017-2022
Figure 6-7: France-Multiple Sclerosis Market (Million US$), 2011-2016
Figure 6-8: France-Forecast for Multiple Sclerosis Market (Million US$), 2017-2022
Figure 7-1: Germany-Multiple Sclerosis Patient Numbers (Thousand), 2011-2016
Figure 7-2: Germany-Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017-2022
Figure 7-3: Germany-Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011-2016
Figure 7-4: Germany-Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017-2022
Figure 7-5: Germany-Multiple Sclerosis Unmet Market (Million US$), 2011-2016
Figure 7-6: Germany-Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017-2022
Figure 7-7: Germany-Multiple Sclerosis Market (Million US$), 2011-2016
Figure 7-8: Germany-Forecast for Multiple Sclerosis Market (Million US$), 2017-2022
Figure 8-1: Italy-Multiple Sclerosis Patient Numbers (Thousand), 2011-2016
Figure 8-2: Italy-Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017-2022
Figure 8-3: Italy-Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011-2016
Figure 8-4: Italy-Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017-2022
Figure 8-5: Italy-Multiple Sclerosis Unmet Market (Million US$), 2011-2016
Figure 8-6: Italy-Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017-2022
Figure 8-7: Italy-Multiple Sclerosis Market (Million US$), 2011-2016
Figure 8-8: Italy-Forecast for Multiple Sclerosis Market (Million US$), 2017-2022
Figure 9-1: Spain-Multiple Sclerosis Patient Numbers (Thousand), 2011-2016
Figure 9-2: Spain-Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017-2022
Figure 9-3: Spain-Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011-2016
Figure 9-4: Spain-Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017-2022
Figure 9-5: Spain-Multiple Sclerosis Unmet Market (Million US$), 2011-2016
Figure 9-6: Spain-Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017-2022
Figure 9-7: Spain-Multiple Sclerosis Market (Million US$), 2011-2016
Figure 9-8: Spain-Forecast for Multiple Sclerosis Market (Million US$), 2017-2022
Figure 11-1: Europe - Number of Neurologists per 100,000 Specialized in MS Vs. Percent of MS Population Receiving DMDs, 2013

List of Tables

Table 10 1: Europe - Reimbursements for Disease Modifying Drugs (DMDs), 2013

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Insulet Corporation
  • Medtronic
  • Tandem Diabetes Care
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll